John M. Kane, MD

How social determinants and care gaps drive schizophrenia relapse—strategies to boost adherence, coordination, and follow-up after hospitalization.

Poorly managed schizophrenia fuels relapse, homelessness and caregiver strain—new data shows most costs are indirect, making prevention and LAIs pivotal.

Poor schizophrenia control drives relapse, homelessness and caregiver strain; data show $367B burden—why relapse prevention and LAIs matter.

Experts share strategies to boost schizophrenia adherence—family partnership, early engagement, and newer antipsychotics to improve long‑term function.

How does John Kane, MD, address issues of cognition in schizophrenia?

John Kane, MD, believes the removal of the REMS requirement for clozapine could help improve utilization for this "grossly underutilized" drug.

John Kane, MD, shares why you should be paying attention to LB-102 for the treatment of schizophrenia.

In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.

A comprehensive discussion on new treatment options for patients with schizophrenia, highlighting the potential for earlier intervention to optimize treatment outcomes.

Compliance is a major issue in treatment of schizophrenia. How can compliance be improved, and can newer formulations make that compliance easier?